Dr.EM_Chicago said:

Liver ultrasound comparison for liver and MASH: my hepatologist ordered serial ultrasounds to track NAFLD regression.

This answered a question I did not know how to ask.

From the other side of the consultation, briefly. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Dr.ReproEndo said:

ATTAIN trial (survodutide) context for liver and MASH: survodutide, a GLP-1/glucagon dual agonist, showed -18.7% body weight at 46 weeks in the Phase…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The objection nobody has made: this only works if the measurement is doing what we assume it is doing, and that assumption has not been tested here.

Adding the numbers, since they settle part of this. One habit that pays for itself: post the method alongside the number. A figure without its method cannot be checked, and an unchecked figure is how this community accumulates folklore.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.